CD274

CD274 (Programmed Cell Death Ligand 1)

Overview

CD274 is the gene encoding programmed cell death ligand 1 (PD-L1), a transmembrane immune checkpoint protein that plays a central role in regulating T-cell-mediated anti-tumor immunity. PD-L1 is expressed on the surface of tumor cells, antigen-presenting cells, and macrophages, where it binds to programmed cell death protein 1 (PD-1) on cytotoxic T cells to suppress immune activation. This interaction delivers an inhibitory signal that promotes immune tolerance, allowing tumors to evade detection and destruction by the adaptive immune system. As a key mediator of tumor-induced immunosuppression, CD274 expression has become one of the most clinically significant biomarkers in oncology, predicting both tumor aggressiveness and response to immunotherapy. The discovery of PD-L1's immunosuppressive role has established CD274 as a critical target for checkpoint inhibitor therapies, fundamentally transforming cancer treatment strategies across multiple malignancies.

Recent Publications Summary

Detection and measurement of CD274/PD-L1 as a diagnostic and prognostic biomarker

Recent advances in biomarker detection have focused on quantifying CD274 expression with high precision in clinical samples. A temperature-compensation microfiber grating sensor coated with gold nanostars and MXene coupled with localized surface plasmon resonance was developed for high-sensitivity tracking of tumor-derived exosomal PD-L1 in human clinical samples 42008957Apr, demonstrating the clinical importance of measuring soluble PD-L1 variants in patient specimens. The prognostic significance of CD274 was further established in epithelial ovarian carcinoma, where researchers evaluated the proportion of PD-L1 expression and its association with clinicopathological features, surgical outcomes, and oncologic survival 42530487Jul, underscoring PD-L1's role as a key survival predictor across cancer types.

Molecular mechanisms controlling CD274 expression

CD274 expression is regulated by complex RNA processing mechanisms. SRSF2, a serine/arginine-rich splicing factor, was identified as a key regulator of PD-L1 expression in gallbladder cancer through an in vitro CRISPR-Cas9 screen, with splicing-mediated control of hnRNPD isoform switching driving PD-L1-dependent immune evasion 42477458Jul. This finding reveals that CD274 regulation involves posttranscriptional control mechanisms beyond simple transcriptional activation. Additionally, osteopontin was shown to mediate acquired resistance to anti-angiogenic therapy by upregulating PD-L1 expression and promoting refractoriness to PD-L1 blockade in breast cancer models, demonstrating how hypoxia-inducing anti-VEGF therapy paradoxically increased CD274 expression while failing to sensitize tumors to checkpoint inhibition 42454487Jul.

Immunomodulatory approaches to enhance CD274-targeted therapy

Emerging strategies seek to enhance anti-tumor immunity by modulating CD274 expression and function. Lactobacillus rhamnosus, a probiotic strain, modulates gut microbiota and tyrosine metabolism to potentiate PD-1-mediated anti-tumor immunity in triple-negative breast cancer, with the mechanism involving inhibition of tumor cell growth via PD-1/PD-L1 interaction 42161051May. Novel molecular approaches have directly targeted CD274 expression through optogenetic editing; a near-infrared biomimetic nanoplatform was used for NIR-II optogenetic CD274 gene editing in head and neck squamous cell carcinoma cells, reducing CD274 expression and improving the efficacy of photoimmunotherapy 41624538Feb. Dual small-molecule inhibitors targeting SHP2 and NAMPT were shown to effectively inhibit proliferation in SHP099-insensitive tumor cell lines and reverse PD-L1-mediated immunosuppression 42324937Jun.

Clinical application and treatment response stratification

The clinical utility of CD274 as a treatment-selection biomarker was demonstrated in gastric and gastroesophageal junction adenocarcinoma, where PD-L1 expression levels determined the benefit of PD-1 antibody plus chemotherapy combinations. Post-hoc analysis of the RATIONALE-305 trial revealed that while multiple phase III trials have established survival benefits of adding PD-1 antibodies to first-line chemotherapy in HER2-negative advanced gastric adenocarcinoma, evidence across different CD274/PD-L1 expression levels remains nuanced, preventing definitive conclusions about the superiority of combination therapy in certain patient subgroups 42477829Jul. These findings highlight the importance of CD274 expression as a predictive biomarker for optimizing checkpoint inhibitor-based treatment strategies and understanding mechanisms underlying resistance to anti-PD-L1 therapies.

What Changes, What Holds

1. Detecting tumor-derived exosomal PD-L1 through plasmonic nanodevices extends CD274 measurement beyond cell surface expression
METHOD Microfiber grating sensors coated with gold nanostars and MXene enable high-sensitivity tracking of soluble PD-L1 variants in patient samples 42008957Apr. This measurement advance focuses on extracellular, exosomal forms of CD274, which the Overview does not address as distinct from membrane-bound PD-L1. Whether soluble variants predict checkpoint inhibitor response as robustly as cell-surface expression remains unclear.

2. PD-L1 expression stratifies surgical and survival outcomes in epithelial ovarian carcinoma
REINFORCES Correlating PD-L1 proportion with clinicopathological features and oncologic outcomes in epithelial ovarian carcinoma 42530487Jul confirms CD274's role as a prognostic marker predicting survival across multiple cancer types. The finding extends the evidence base to a specific histology without challenging the Overview's account of how PD-L1 mediates immune evasion and influences survival outcomes.

3. RNA splicing emerges as a regulatory node controlling CD274 expression in tumor cells
NEW DIRECTION SRSF2, a serine/arginine-rich splicing factor, drives PD-L1 expression in gallbladder cancer via splicing-mediated control of hnRNPD isoforms 42477458Jul. The Overview treats CD274 expression as transcriptionally regulated but does not discuss RNA processing or splicing-based mechanisms. Posttranscriptional control through alternative splicing represents a distinct regulatory layer the baseline has not addressed.

4. Osteopontin-mediated CD274 upregulation reduces responsiveness to anti-VEGF plus checkpoint inhibition
NEW DIRECTION Osteopontin promotes acquired resistance to anti-angiogenic therapy by upregulating PD-L1 and blocking sensitivity to PD-L1 blockade in breast cancer models 42454487Jul. This describes CD274 serving resistance to combination therapy, revealing a mechanism by which hypoxia-mediated checkpoint elevation undermines intended immunotherapy benefits, complicating the therapeutic logic of adding checkpoint inhibitors to anti-angiogenic regimens.

5. Probiotics enhance anti-tumor immunity through PD-1/PD-L1 interaction
NEW DIRECTION Lactobacillus rhamnosus modulates gut microbiota and tyrosine metabolism to potentiate PD-1-mediated anti-tumor immunity in triple-negative breast cancer 42161051May, with tumor growth inhibited via the CD274/PD-L1 interaction. CD274 can facilitate rather than suppress anti-tumor T cell responses when immune activation is primed by probiotics, complicating the Overview's assertion that PD-L1 uniformly delivers inhibitory signals promoting immune tolerance.

6. Optogenetic editing of CD274 directly reduces expression and improves photoimmunotherapy efficacy
METHOD A near-infrared biomimetic nanoplatform enables optogenetic CD274 gene editing to reduce expression in head and neck squamous cell carcinoma cells 41624538Feb. Spatially controlled optogenetic suppression of CD274 represents a direct approach to manipulating the entity beyond pharmacological blockade, introducing precision genome editing as a study and potentially therapeutic technique.

7. SHP2 and NAMPT dual inhibition reverses PD-L1-mediated immunosuppression in checkpoint inhibitor-resistant tumors
NEW DIRECTION Small-molecule inhibitors targeting both SHP2 and NAMPT overcome PD-L1-driven immune evasion in SHP099-insensitive cell lines 42324937Jun. Identifying downstream effectors through which CD274 sustains immune escape expands therapeutic rationale beyond anti-PD-L1 monotherapy, opening alternative targets for tumors that evade initial checkpoint blockade.

8. CD274 expression does not stratify checkpoint inhibitor response in gastric adenocarcinoma
PARADIGM SHIFT CD274 expression levels did not distinguish responders from non-responders in the RATIONALE-305 trial 42477829Jul, despite PD-1 antibodies conferring survival benefit when added to first-line chemotherapy. Gastric adenocarcinoma data contradict the Overview's assertion that CD274 is a predictive biomarker for immunotherapy response, as the expression-outcome relationship remains too nuanced to guide patient stratification in this histology.

Overview update candidates: entry 8.